新闻中心

新闻中心

News Center
All Categories
Company News
Industry News

The company participated in the 12th National Academic Conference on Psychiatry

Release Time

2022-06-22 10:55

From September 11 to 14, 2014, the 12th National Academic Conference on Psychiatry of the Chinese Medical Association, organized by the Psychiatry Branch of the Chinese Medical Association and undertaken by the Shaanxi Medical Association, was held in Xi'an. The number of registered participants in this conference reached more than 1,700. .

With the theme of "Integrating Psychology and Drug Therapy to Obtain the Best Clinical Benefit", the conference focused on the pathological mechanism of mental disorders, comorbidities, substance dependence, drug therapy for schizophrenia and bipolar disorder, cognitive behavioral therapy, etc. A wealth of thematic academic exchanges have been carried out. The conference invited Professor Yu Xin, Professor Shi Shenxun, Professor Zhao Jingping, Professor Huang Chirong, Professor Jing Jin and other famous scholars at home and abroad to give academic reports. This conference is of great significance to the discipline development and personnel training of psychiatry.

The company participated in the image display of the booth and held the "Oranzhi" satellite conference, and invited Professor Lu Zheng from the Shanghai Mental Health Center to give a special academic report on "long-term maintenance treatment and drug selection for schizophrenia". This is the first time the company has participated in a national psychiatry conference. Both the booth and the satellite conference have attracted many participating doctors, and have won wide recognition and support. It is a firm step for the company to implement the strategy of focusing on the field of psychiatry and its long-term development. step.

 

Conference site

 

Booth

 

Satellite Symposium

 

Previous page

The company obtained the new version of GSP certification

Statement on guarding against criminals recruiting under the name of the company

Next page

Previous page

The company obtained the new version of GSP certification

Next page

Statement on guarding against criminals recruiting under the name of the company

Related News

Foncoo Pharmaceutical participated in the 19th National Psychiatry Academic Conference of the Chinese Medical Association

Foncoo Pharmaceutical participated in the 19th National Psychiatry Academic Conference of the Chinese Medical Association

Sponsored by the Chinese Medical Association and the Psychiatry Branch of the Chinese Medical Association, and organized by the Chongqing Medical Association, the Psychiatry Branch of the Chongqing Medical Association, the First Affiliated Hospital of Chongqing Medical University, and the University City Hospital Affiliated to Chongqing Medical University The conference and the Academic Conference on Child and Adolescent Psychiatry were successfully held at Chongqing Yuelai International Conference Center from December 21 to 24, 2021.

2022-05-25

图片名称
2021-Foncoo Public Welfare

2021-Foncoo Public Welfare

On October 15, 2021, Foncoo Pharmaceutical donated 100,000 yuan in cash to the "Gu Xueqiu Pharmacy Education Fund" public welfare student aid project of the Beijing Renren Public Welfare Foundation-Shenyang Pharmaceutical University.

2022-05-25

图片名称
Foncoo Pharmaceutical's corporate culture 5.0 was officially released

Foncoo Pharmaceutical's corporate culture 5.0 was officially released

Official announcement! Seriously, don't be distracted!

2022-05-25

图片名称
Foncoo Pharmaceutical participated in the 16th National Academic Conference on Psychiatric Hospital Management

Foncoo Pharmaceutical participated in the 16th National Academic Conference on Psychiatric Hospital Management

On October 29-31, 2021, the 16th National Academic Conference on Psychiatric Hospital Management, hosted by the Chinese Hospital Association and the Chinese Hospital Association Psychiatric Hospital Branch, was held in Chongqing.

2022-05-25

图片名称

"Bupropion Hydrochloride Sustained-Release Tablets (II)" exclusively sold by Foncoo Pharmaceuticals was approved in China

Recently, "Bupropion Hydrochloride Sustained-Release Tablets (II) (150mg, 300mg)", exclusively sold by Pangu Pharmaceuticals (Mainland China), was approved by the State Drug Administration and deemed to have passed the consistency evaluation. The product, developed by Shanghai Xuantai Pharmaceuticals, was previously approved by the FDA in August 2017 and was marketed in the United States.

2022-05-25

图片名称
Foncoo Pharmaceutical participated in the 9th China Schizophrenia Forum

Foncoo Pharmaceutical participated in the 9th China Schizophrenia Forum

From October 22 to 24, 2021, the "Ninth China Schizophrenia Forum" was grandly held in Wuhan. The theme of this forum is "Infection, Inflammation and Schizophrenia".

2022-05-25

图片名称